| Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide V Marconi, S Bonhoeffer, R Paredes, J Lu, R Hoh, JN Martin, SG Deeks, ... Journal of acquired immune deficiency syndromes (1999) 48 (5), 572, 2008 | 23 | 2008 |
| The potential role of interleukin-2 in patients with HIV infection R Paredes, JCLB de Quiros, E Fernández-Cruz, B Clotet, HC Lane AIDS Rev 4, 36-40, 2002 | 23 | 2002 |
| Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse … SL Pett, J Amin, A Horban, J Andrade-Villanueva, M Losso, N Porteiro, ... Clinical Infectious Diseases 63 (1), 122-132, 2016 | 22 | 2016 |
| A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy R Paredes, MC Puertas, W Bannister, M Kisic, A Cozzi-Lepri, C Pou, ... Journal of Infectious Diseases 204 (5), 741-752, 2011 | 22 | 2011 |
| Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation R Paredes, PL Tzou, G Van Zyl, G Barrow, R Camacho, S Carmona, ... PLoS One 12 (7), e0181357, 2017 | 21 | 2017 |
| Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants M Noguera-Julian, A Cozzi-Lepri, F Di Giallonardo, R Schuurman, ... Clinical microbiology and infection 22 (2), 191-200, 2016 | 21 | 2016 |
| Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: the data collection on adverse events of … H Kovari, CA Sabin, B Ledergerber, L Ryom, P Reiss, M Law, C Pradier, ... Open forum infectious diseases 3 (1), 2016 | 21 | 2016 |
| Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4 D Nicolás, J Ambrosioni, R Paredes, MÁ Marcos, C Manzardo, A Moreno, ... Expert review of anti-infective therapy 13 (8), 947-963, 2015 | 21 | 2015 |
| HIV resistance testing and detected drug resistance in Europe A Schultze, AN Phillips, R Paredes, M Battegay, JK Rockstroh, L Machala, ... Aids 29 (11), 1379-1389, 2015 | 21 | 2015 |
| Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211 AMN Tsibris, R Paredes, A Chadburn, Z Su, TJ Henrich, A Krambrink, ... Clinical infectious diseases 48 (5), 642-649, 2009 | 21 | 2009 |
| The evolving landscape of HIV drug resistance diagnostics for expanding testing in resource-limited settings SC Inzaule, RL Hamers, R Paredes, C Yang, R Schuurman, ... AIDS Rev 19 (4), 219-230, 2017 | 20 | 2017 |
| Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy WP Bannister, A Cozzi-Lepri, J Kjær, B Clotet, A Lazzarin, JP Viard, ... Journal of antimicrobial chemotherapy 66 (4), 901-911, 2011 | 20 | 2011 |
| " Therapy: it's a two-way thing": women survivors of child sexual abuse describe their therapy experiences K McGregor PhD Thesis-University of Auckland, 2003 | 20 | 2003 |
| Evolution of the gut microbiome following acute HIV-1 infection M Rocafort, M Noguera-Julian, J Rivera, L Pastor, Y Guillén, J Langhorst, ... Microbiome 7 (1), 73, 2019 | 19 | 2019 |
| Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors S Franco, R Bellido, E Aparicio, N Canete, M García‐Retortillo, R Sola, ... Journal of viral hepatitis 18 (10), e578-e582, 2011 | 19 | 2011 |
| In–depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection J Dalmau, FM Codoñer, I Erkizia, M Pino, C Pou, R Paredes, B Clotet, ... PloS one 7 (2), e32714, 2012 | 18 | 2012 |
| Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 … E Negredo, R Paredes, A Bonjoch, A Tuldra, CR Fumaz, S Gel, B Garces, ... Antiviral therapy 4, 23-28, 1999 | 18 | 1999 |
| Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing ER Lee, N Parkin, C Jennings, CJ Brumme, E Enns, M Casadellà, ... Scientific reports 10 (1), 1-10, 2020 | 17 | 2020 |
| Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study E Negredo, R Paredes, J Peraire, E Pedrol, H Côté, S Gel, CR Fumaz, ... Antivir Ther 9 (6), 889-93, 2004 | 17 | 2004 |
| Simplification of antiretroviral treatment from darunavir/ritonavir monotherapy to darunavir/cobicistat monotherapy: effectiveness and safety in routine clinical practice JR Santos, A Curran, J Navarro-Mercade, MF Ampuero, P Pelaez, ... AIDS research and human retroviruses 35 (6), 513-518, 2019 | 16 | 2019 |
Bonaventura ClotetDirector irsiCaixa AIDS Research InstituteVerified email at irsicaixa.es
